VAF347 is a cell permeable and highly affinity aryl hydrocarbon receptor (AhR) agonist and induces AhR signaling. VAF347 inhibits the development of CD14+CD11b+ monocytes from granulo-monocytic (GM stage) precursors. VAF347 has anti-inflammatory effects.

CA-5f is a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer.

CaCC(inh)-A01 is a non-selective inhibitor of calcium-activated chloride channels (CaCCs) that blocks ATP-stimulated chloride conductance in human salivary gland, intestinal, and bronchial epithelium (mean IC50 = 10 µM).

Cadazolid (ACT-179811) is a novel fluoroquinolone-oxazolidinone antibiotic and a protein synthesis inhibitor.

Calcitonin, Salmon is a calcium regulating hormone secreted from mammalian thyroid parafollicular cells and in non-mammalian species from the ultimobranchial gland.

calpeptin is Ca2+-dependent protease,calpain inhibitor

Cambinol is a SIRT1 and SIRT2 inhibitor with IC50 values of 56 and 59 μM, respectively.

PROTAC-VHL-ligand is a von Hippel–Lindau (VHL) ligand used for the proteolysis targeting chimeras (PROTACs) method, induces target protein degradation..

Cardiogenol C is a diaminopyrimidine that induces cardiomyogenesis in mouse embryonic stem cells.

CAY10441 is a Selective prostacyclin IP receptor antagonist.

CAY10465 is an analog of resveratrol acting as a potent and selective aryl hydrocarbon receptor agonist, with a Ki of 0.2 nM.

CAY10602 is a SIRT1 activator.

CB-03-01 is a steroidal ester, androgen antagonist derived from 11-deoxycortisone, which tightly mimics the profile of an ideal anti-androgen for topical use.

CB7921220 is an inhibitor of Adenylyl Cyclase isoform-1 (AC1) and isoform-6 (AC6).

CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3Kα (IC50=4 μM).

CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

CCG215022 is a G protein-coupled receptor kinases (GRKs) inhibitor with IC50s of 0.15±0.07 μM, 0.38±0.06 μM and 3.9±1 μM for GRK2, GRK5 and GRK1, respectively.

CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity.

CCT244747 represents the first structural disclosure of a highly selective, orally active CHK1 inhibitor and warrants further evaluation alone or combined with genotoxic anticancer therapies.

CDC25 Phosphatase Inhibitor I, BN82002, is a cell-permeable ortho-hydroxybenzylamino compound that has been reported to display antitumor properties.

CDDO-2P-Im is a new analogue of CDDO-Imidazolid,showing better bioactive than CDDO-Imidazolid.

CDDO-3P-Im is a new analogue of CDDO-Imidazolid,showing better bioactive than CDDO-Imidazolid.

CDDO-imidazolide is a potent inducer of heme oxygenase-1 and Nrf2/ARE signaling,with potent antiproliferative, differentiating, and anti-inflammatory activities.

C-DIM12 is a novel synthetic activator of Nurr1.

CDK2 inhibitor 73 is a potent, selective CDK2 inhibitor with IC50 of 44 nM for CDK2/cyclin A, displays 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM)..

Rafutrombopag is a thrombopoietin (TPO) agonist extracted from patent CN113929668 A.

TGFβR-IN-1 is a long-acting tumor-activated prodrug of a TGFβR inhibitor.

6-Bnz-cAMP sodium salt is a cell-permeable cAMP analog. 6-Bnz-cAMP selectively activates cAMP-dependent PKA but not Epac signaling pathways.

SHP2 protein degrader-1 is a potent allosteric inhibitor of SHP2. SHP2 protein degrader-1 induces SHP2 degradation and cell apoptosis. SHP2 protein degrader-1 has the potential for the treatment of SHP2 related diseases.

Orexin B, rat, mouse (Rat orexin B) TFA is an endogenous orexin receptor agonist. Orexin B, rat, mouse TFA binds and activates two closely related orphan G protein-coupled receptors OX1-R and OX2-R. Orexin B, rat, mouse TFA stimulates food intake and energy expenditure and plays a significant role in sleep-wakefulness regulation.